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Abstract 
Context: A four marker haplotype in the 5’ region of the Fc receptor-like 3 gene (markers 
FCRL3_3 to FCRL3_6) has recently been identified as contributing to rheumatoid arthritis 
susceptibility in the Japanese population. The promoter FCRL3_3*C allele also showed 
significant association with autoimmune thyroid disease and systemic lupus erythematosus. 
These findings raise the possibility that this locus may influence autoimmune disease 
susceptibility across many populations.  
Patients and Design: We analysed the same four 5’ FCRL3 SNP markers, together with three 
additional exonic SNPs in the FCRL3 gene, in cohorts of white Caucasians with Graves’ disease 
(n=625), type 1 diabetes (n=279), autoimmune Addison’s disease (n=200) and rheumatoid 
arthritis (n=769). Healthy controls from the UK (n=490) and New Zealand (n=593) were used. 
Results: Six of the seven FCRL3 markers showed association with autoimmune Addison’s 
disease (p=0.005 to 0.0001), with maximum evidence at the FCRL3_3*T allele 
(p[corrected]=0.0008; odds ratio 1.61; 5-95% confidence intervals 1.26 to 2.05). The most common 
seven marker FCRL3 haplotype (TGGGAAA) was also found to be significantly associated with 
autoimmune Addison’s disease p[corrected]=1.1x10-4; odds ratio 1.71; 5-95% confidence intervals 
1.33-2.18). There was nominal evidence for allelic association at the marker FCRL3_8 in Graves’ 
disease (OR 1.50; 5-95% CI 1.06-2.13) and at FCRL3_9 with rheumatoid arthritis (OR 1.25; 5-
95% CI 1.01-1.54).  
Conclusions: The FCRL3 haplotype that is associated with autoimmune Addison’s disease in 
Caucasians appears to be protective for autoimmune diseases in the Japanese population, 
demonstrating that this haplotype is unlikely to contain a single primary etiological allele for 
autoimmunity. Our observations suggest that the susceptibility to autoimmunity at the FCRL3 
locus is more complex than initially thought, and may extend either side of the currently 
associated region, to include the adjacent FCRL2 gene. 
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Introduction 
Autoimmune endocrinopathies, together with immune-mediated rheumatological disorders 
contribute the major burden of disease caused by autoimmunity in the population, with around 
5% of women in developed societies being affected by such conditions. All the common 
autoimmune conditions have a complex genetic basis, with autoimmune endocrinopathies and 
rheumatoid arthritis (RA) commonly occurring in the same individual and clustering within 
families [1]. Graves’ disease (GD), RA, and type 1 diabetes (T1D) are frequent disorders 
(prevalence 0.4-1%), and each has a !s (ratio of risk to sibling vs unrelated background 
population) of between 7 and 15, suggesting a significant genetic component to susceptibility. In 
contrast, autoimmune Addison’s disease (AAD) is a much rarer condition with a prevalence of 
about 1 per 10,000 people in the UK [2] but a risk to first-degree relatives of about 2%, 
suggesting a more marked genetic influence on disease susceptibility. Whole-genome linkage 
studies have shown clustering of susceptibility loci for many of these different disorders and 
several loci consistently appear to contribute to multiple forms of autoimmunity across diverse 
populations. Examples of such loci include the major histocompatibility complex (MHC) [3,4], 
the cytotoxic T lymphocyte antigen-4 gene (CTLA4) [5-10] and the protein tyrosine phosphatase 
non-receptor type 22 gene (PTPN22) [11-13]. A second class of autoimmunity susceptibility 
locus is represented by the disease-specific loci, such as the insulin gene (INS, IDDM2) [14], or 
the thyrotropin receptor [15,16] whose contribution is unique to the relevant target tissue or 
specific antigen of the autoimmune response. A final class of loci are those where replicable 
disease associations are found in some populations studied, but for which there appears to be little 
or no contribution to disease in well-powered studies of other populations. For example the 
PADI4 gene is associated with RA in the Japanese population [17-19] but with a weak effect, 
only demonstrable by meta-analysis, in European populations [20-22]. Thus, it remains 
imperative to study putative autoimmune disease susceptibility alleles in different autoimmune 
conditions and also in several populations of varied ethnic background. The latter approach, 
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sometimes termed “transracial mapping” can give important clues to the identity of aetiologically 
important alleles [23]. 
 
One recently identified novel susceptibility gene in rheumatoid arthritis is the Fc receptor-like 3 
gene (FCRL3) [24], located at 1q21, a region implicated in susceptibility to several autoimmune 
diseases in whole-genome linkage studies [25-27]. Kochi et al. identified a four single nucleotide 
polymorphism (SNP) haplotype (FCRL3_3 to FCRL3_6) as being associated with RA in two 
separate cohorts of Japanese patients. The greatest association with RA (p=8.5x10-7; odds ratio 
2.15) was found in individuals who were homozygote carriers of a particular promoter allele, 
FCRL3_3*C, at position -169 relative to the FCRL3 transcription start site. This allele 
(FCRL3_3*C ) was also found to be associated in Japanese cohorts with autoimmune thyroid 
disease (p=1.7x10-5; odds ratio 1.74) and systemic lupus erythematosus (p=0.0017; odds ratio 
1.49). This same allele was also found to produce higher promoter activity in a reporter gene 
assay and to be more avidly bound by NF"B in gel-shift studies, suggesting a direct functional 
role [24]. FCRL3 is an orphan cell-surface receptor with homology to the Fc immunoreceptors, 
and is expressed predominantly in B-lymphocytes in lymph node germinal centres. In this study 
we have analysed the same 4 marker FCRL3 SNP haplotype and 3 additional exonic SNP 
markers in four cohorts of white Caucasians with autoimmune disorders including GD, AAD, RA 
and T1D. 
 
Materials and Methods 
Subjects 
The GD (n=625) and AAD (n=105) probands were recruited through endocrine and combined 
physician-ophthalmologist thyroid associated ophthalmopathy clinics at the Newcastle upon Tyne 
Hospitals Trust and surrounding district hospitals. A further cohort of 95 AAD probands were 
recruited via the UK Addison’s disease self-help group. The diagnostic criteria of these cohorts 
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have been published previously [28,29]. Of the GD probands 78% were female, 38% had 
significant thyroid associated opthalmopathy (NOSPECS class 3 or worse) and 55% were 
smokers. The UK GD subjects all had parents born in the North-East of England. Isolated AAD 
accounted for 36% of the AAD cohort, the other 64% had at least one other associated 
autoimmune disease (hypothyroidism, 77; Graves’ disease, 24; primary gonadal failure, 23; type 
1 diabetes, 12; pernicious anaemia, 13; vitiligo, 6; celiac disease, 6; rheumatoid arthritis, 4; 
alopecia, 3; haemolytic anaemia, 2; and autoimmune hepatitis, 1). The AAD cohort included 151 
females (75.5%) and 49 males (24.5%). The mean age of onset was 40 years old. Four of the 200 
AAD probands also had an affected first degree relative with AAD (two siblings, two offspring). 
None of the AAD subjects had autoimmune hypoparathyroidism or candidiasis (subjects with 
type 1 polyendocrinopathy were excluded from the cohort) [28].  UK controls (n=490; 66.3% 
females, 33.7% males) also recruited from the local population had no clinical features or family 
history of autoimmune disease. The RA (n=769) cases were recruited from rheumatology clinics 
throughout New Zealand and details of their clinical characterisation, and of the NZ control 
cohort (n=563) have previously been published [13].  The T1D cohort comprised 279 subjects 
with hyperglycaemia and ketosis who were commenced on insulin therapy at diagnosis, recruited 
from endocrinology clinics throughout New Zealand. They had an average age of onset of 12.5 
years.  
  
SNP genotyping 
The SNPs within the 4-marker haplotype described by Kochi et al (2005) [24] were genotyped 
either by PCR and restriction enzyme digest (RFLP) (UK cohort SNPs FCRL3_3, 3_4; NZ cohort 
FCRL3_3 to 3_6) or primer extension-MALDI-TOF assay (Sequenom, Inc., San Diego, CA) (UK 
cohort SNPs FCRL3_5, 3_6). Furthermore, we examined three additional exonic FCRL3 SNPs, 2 
of which are non-synonymous cSNPs. The additional markers were located as follows: 
rs7522061 -exon 3 cSNP (D28N); rs2282284 (FCRL3_8) exon 14 cSNP (N721S); rs2282283 
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(FCRL3_9) -3’UTR (Figure 1) and were genotyped by PCR/RFLP (UK cohort SNP D28N; NZ 
cohort D28N, FCRL3_8 & 3_9) or primer extension-MALDI-TOF assay (UK cohort SNPs 
FCRL3_8, 3_9). Details of the assay oligonucleotide sequences and conditions are available from 
the authors (shown in supplementary table 1). 
 
Statistical analysis 
The case-control association studies were analysed using #2 tests on 2x2 and 2x3 contingency 
tables for allele and genotype frequencies, respectively. Haplotype frequencies were estimated, 
and linkage disequilibrium (r2) measures were calculated using the SHEsis package [30]. Odds 
ratios and confidence intervals were calculated using Woolf’s method. No significant deviation 
from Hardy Weinberg equilibrium was observed for any of the SNPs in this study (all p>0.05). 
The overall genotype call rate was 98.2% (range 91.6-100%), and the accuracy was >99% 
according to duplicate genotyping of 7-10% of samples. We estimate that our studies of GD and 
RA had more than 80% power to detect an effect ($=0.001) of the same magnitude (allelic odds 
ratio of 1.4) as that found in the Japanese GD cohorts [24], using our control allele frequencies 
and a binomial model. The power of our studies of AAD and T1D were >80% and >90%, 
respectively, assuming an allelic odds ratio of 1.4 ($=0.05). P values were Bonferroni corrected 
for multiple tests assuming that the 7 SNP markers carried information for 4 independent linkage 
groups, and that each of the 4 disease states were independent.  
 
 
Results 
We found significant linkage disequilibrium between markers at the 5’ end of FCRL3, but lesser 
association between the other 3’ alleles, with pairwise r2 values based on the UK control 
population as follows: FCRL3_3 – [0.412]– FCRL3_4 – [0.410] –FCRL3_5 – [0.987] – FCRL3_6 
– [0.915] – N28D – [0.088] – FCRL3_8 – [0.024] – FCRL3_9 (Figure 1). The corresponding 
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figures for the NZ control population are: FCRL3_3 – [0.396]– FCRL3_4 – [0.420] –FCRL3_5 – 
[0.834] – FCRL3_6 – [0.749] – N28D – [0.068] – FCRL3_8 – [0.011] – FCRL3_9. In contrast to 
the finding of strong association with disease of the FCRL3_3 to FCRL3_6 SNPs in Japanese RA 
and GD subjects, we could find no evidence to support disease association with alleles at any of 
these markers in UK whites with GD or in NZ whites with RA or T1D (Table 1). Markers in the 
3’ end of the gene showed nominal evidence for association at FCRL3_8 in Graves’ disease (A 
allele, OR 1.50; 5-95% confidence intervals 1.06-2.13) and at FCRL3_9 in RA (C allele, OR 
1.25; 5-95% confidence intervals 1.01-1.54), however, these findings were not robust to 
correction for multiple statistical testing (Table 1). 
 
In contrast, there was substantial allelic association at 6 of the 7 FCRL3 markers studied in the 
cohort of UK subjects with autoimmune Addison’s disease, with maximum evidence at 
FCRL3_3. The T allele of this marker (FCRL3_3*T) was present in 254 of 400 (63.5%) AAD 
chromosomes compared to 467 of 898 (52.0%) control chromosomes (p[corrected]=0.0008; OR 
1.61; 5-95% confidence intervals 1.26 to 2.05) (Table 1). The most common seven marker 
haplotype containing the FCRL3_3*T allele [TGGGAAA] was also significantly associated with 
AAD, p=1.8 x10-5, p[corrected]=1.1x10-4 (odds ratio 1.71; 5-95% confidence intervals 1.33-2.18), 
with a p value of 0.001 using a global test of the 6 common haplotypes found in the AAD patients 
(Table 2). There were no significant haplotype associations with disease in either of the GD, RA 
or T1D cohorts (Table 2). There was no significant heterogeneity in the allelic associations in the 
various cohorts when divided by diagnostic subgroups (supplementary table 2). 
 
Discussion 
The association of multiple autoimmune disorders in the Japanese population with alleles of 
FCRL3 by Kochi and colleagues [24] suggested that this locus may affect susceptibility to 
different autoimmune diseases across many populations, in a similar way to the action of alleles 
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at CTLA4 [5-10]. The association of the FCRL3_3*C allele with susceptibility to autoimmune 
conditions found in this initial study has recently been replicated in a further cohort of Japanese 
subjects with rheumatoid arthritis (n=752) [31]. Furthermore, a study of a white UK population 
showed a weak effect in Graves’ disease, with FCRL3 markers having nominal association 
(FCRL3_3*C, p=0.024, OR 1.17) [32]. However, similar investigation of several additional large 
cohorts of Caucasian subjects with T1D and RA have failed to replicate the FCRL3_3 association 
[33-36]. In contrast to these studies, our investigation found that the FCRL3_3*C allele was 
associated with protection from autoimmune Addison’s disease; an observation that largely 
refutes the hypothesis that this allele is the disease-causing polymorphism for autoimmunity at 
this locus, at least not in Caucasians. In addition, our extended genotyping points to the exon 3 
cSNP (D28N) as also being tightly associated with FCRL3_3 (r2 > 0.9; Figure 1) and this marker 
certainly warrants examination in Japanese and other autoimmune disease cohorts. While our 
analyses of rheumatoid arthritis and Graves’ disease were well-powered to detect an effect of 
similar magnitude to that found in the Japanese cohorts, only marginal evidence for association 
was found in these conditions; this being found at the 3’ FCRL3 SNPs (designated FCRL3_9 and 
FCRL3_8, respectively), which are not in the haplotype block containing the promoter and exon 3 
markers (Figure 1). 
  
The contradiction of the apparent protection conferred in the Addison’s disease cohort by the 
Japanese autoimmune susceptibility haplotype could be explained in three ways. Firstly, the 
association reported here in the AAD cohort could be a chance finding. It is important that other 
AAD cohorts are genotyped for the FCRL3 variants analysed here. However, genotype data at 
other loci do not support population stratification or mismatching between the AAD cohort and 
UK controls as an explanation for this result [37,38; supplementary table 3]. Secondly, the 
disparate FCRL3 genetic association could reflect genuine differences in FCRL3-mediated 
autoimmune disease aetiology between the Japanese and Caucasian populations. In addition, it is 
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possible that different immunopathological mechanisms underlie the disease process in AAD 
compared to RA, GD and the other more common autoimmune diseases. With this regard, the 
lower promoter activity of the FCRL3_3*T allele that would be predicted based on the existing 
functional analysis at this locus [24], could have a distinct pathogenic role in AAD, but still be 
protective for other forms of autoimmunity. Lastly, the susceptibility allele at FCRL3 may lie 
elsewhere within the block of linkage disequilibrium that contains the 5’ region of the FCRL3 
gene, or within the adjacent FCRL2 transcript (figure 1). The 5’ region of FCRL3 is in an LD 
block which extends across an intragenic region to the 3’ end of the FCRL2 gene, including 
several coding FCRL2 exons. In addition, the 3’ region of FCRL3 (centromeric to exon 5 and 
encoding the critical cytoplasmic tail of the receptor) is sparsely covered by existing markers and 
appears to contain a substantial interval with weak or no LD between markers [39]. Furthermore, 
there may be additional subtle differences in LD structure between Japanese and Caucasians at 
this locus that will not be evident until a denser marker-map is genotyped. Evidence for 
association of FCRL3 promoter alleles with autoimmune disease is currently consistent in 
Japanese populations but equivocal or absent in most Caucasian populations (32-36). To further 
clarify a possible role for this locus in autoimmunity in Caucasians, our findings suggest that 
more detailed genetic analysis of an extended haplotype block containing both FCRL3 and 
FCRL2 is warranted. 
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Legend for figure 1.  Linkage disequilibrium r2 measures for FCRL3 in the UK control 
population. In the schematic diagram of the FCRL3 gene, exons are depicted by black boxes and 
non-coding regions as white boxes. The position of the seven SNPs (FCRL3_3,-4,-5,-6, N28D, -
8,-9) spanning 22.435 kb of the FCRL3 gene region are shown. 
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